Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer

NCT05681390 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Neoplasms

Interventions

DRUG: Tislelizumab

Sponsor

First Affiliated Hospital Xi'an Jiaotong University